AMPH
Price
$19.94
Change
-$0.44 (-2.16%)
Updated
Jul 31 closing price
Capitalization
879.21M
7 days until earnings call
Intraday BUY SELL Signals
ANIP
Price
$79.24
Change
-$1.19 (-1.48%)
Updated
Jul 31 closing price
Capitalization
1.8B
9 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMPH vs ANIP

AMPH vs ANIP Comparison Chart in %
View a ticker or compare two or three
VS
AMPH vs. ANIP commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMPH is a Buy and ANIP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 03, 2026
Stock price -- (AMPH: $19.94 vs. ANIP: $79.24)
Brand notoriety: AMPH and ANIP are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: AMPH: 47% vs. ANIP: 52%
Market capitalization -- AMPH: $879.21M vs. ANIP: $1.8B
AMPH [@Pharmaceuticals: Generic] is valued at $879.21M. ANIP’s [@Pharmaceuticals: Generic] market capitalization is $1.8B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMPH’s FA Score shows that 1 FA rating(s) are green whileANIP’s FA Score has 0 green FA rating(s).

  • AMPH’s FA Score: 1 green, 4 red.
  • ANIP’s FA Score: 0 green, 5 red.
According to our system of comparison, ANIP is a better buy in the long-term than AMPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMPH’s TA Score shows that 6 TA indicator(s) are bullish while ANIP’s TA Score has 3 bullish TA indicator(s).

  • AMPH’s TA Score: 6 bullish, 3 bearish.
  • ANIP’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, AMPH is a better buy in the short-term than ANIP.

Price Growth

AMPH (@Pharmaceuticals: Generic) experienced а +6.52% price change this week, while ANIP (@Pharmaceuticals: Generic) price change was +2.05% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.61%. For the same industry, the average monthly price growth was -5.02%, and the average quarterly price growth was +19.02%.

Reported Earning Dates

AMPH is expected to report earnings on Aug 10, 2026.

ANIP is expected to report earnings on Aug 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.61% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ANIP($1.8B) has a higher market cap than AMPH($879M). ANIP has higher P/E ratio than AMPH: ANIP (20.27) vs AMPH (12.01). ANIP YTD gains are higher at: 0.380 vs. AMPH (-25.541). ANIP has higher annual earnings (EBITDA): 224M vs. AMPH (193M). ANIP has more cash in the bank: 326M vs. AMPH (292M). ANIP has less debt than AMPH: ANIP (614M) vs AMPH (686M). ANIP has higher revenues than AMPH: ANIP (924M) vs AMPH (721M).
AMPHANIPAMPH / ANIP
Capitalization879M1.8B49%
EBITDA193M224M86%
Gain YTD-25.5410.380-6,721%
P/E Ratio12.0120.2759%
Revenue721M924M78%
Total Cash292M326M90%
Total Debt686M614M112%
FUNDAMENTALS RATINGS
AMPH vs ANIP: Fundamental Ratings
AMPH
ANIP
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
10038
SMR RATING
1..100
7152
PRICE GROWTH RATING
1..100
7055
P/E GROWTH RATING
1..100
1598
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMPH's Valuation (53) in the Pharmaceuticals Other industry is in the same range as ANIP (84). This means that AMPH’s stock grew similarly to ANIP’s over the last 12 months.

ANIP's Profit vs Risk Rating (38) in the Pharmaceuticals Other industry is somewhat better than the same rating for AMPH (100). This means that ANIP’s stock grew somewhat faster than AMPH’s over the last 12 months.

ANIP's SMR Rating (52) in the Pharmaceuticals Other industry is in the same range as AMPH (71). This means that ANIP’s stock grew similarly to AMPH’s over the last 12 months.

ANIP's Price Growth Rating (55) in the Pharmaceuticals Other industry is in the same range as AMPH (70). This means that ANIP’s stock grew similarly to AMPH’s over the last 12 months.

AMPH's P/E Growth Rating (15) in the Pharmaceuticals Other industry is significantly better than the same rating for ANIP (98). This means that AMPH’s stock grew significantly faster than ANIP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AMPHANIP
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
61%
Bearish Trend 4 days ago
72%
Momentum
ODDS (%)
Bullish Trend 4 days ago
71%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
70%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
67%
Bearish Trend 4 days ago
68%
Advances
ODDS (%)
Bullish Trend 6 days ago
76%
Bullish Trend 6 days ago
73%
Declines
ODDS (%)
Bearish Trend 4 days ago
70%
Bearish Trend 4 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 4 days ago
79%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
AMPH
Daily Signal:
Gain/Loss:
ANIP
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IREZ16.251.05
+6.91%
Tradr 2X Short Iren Daily ETF
FSGS32.550.02
+0.07%
First Trust SMID Growth Strength ETF
PVI24.83-0.01
-0.06%
Invesco Floating Rate MunicipalIncomeETF
IAI186.26-0.63
-0.34%
iShares US Broker-Dealers&Secs Exchs ETF
HSCZ42.75-0.27
-0.63%
iShares Currency Hdgd MSCI EAFE SmCp ETF